Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-blind Placebo Controlled, Randomized, Phase II Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients

Trial Profile

A Double-blind Placebo Controlled, Randomized, Phase II Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Dec 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Teslexivir (Primary)
  • Indications Condylomata acuminata
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Anaconda Pharma; Aviragen Therapeutics; Vaxart
  • Most Recent Events

    • 09 Nov 2018 According to a Vaxart media release, following the completion of the 3-month follow-up assessment in this study, analysis of the data showed there was no improvement compared to the topline results reported in June 2018.
    • 18 Jul 2018 Status changed from active, no longer recruiting to completed.
    • 04 Jun 2018 According to a Vaxart media release, patients are undergoing 3 months follow-up period to assess for condyloma recurrence.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top